Development and validation of a high-throughput radiometric CYP2C9 inhibition assay using tritiated diclofenac

Drug Metabolism and Disposition

Volumn 33, Issue 3, 2005, Pages 359-364

  Di Marco, Annalise ^a   Marcucci, Isabella ^a   Chaudhary, Ashok ^b   Taliani, Marina ^a   Laufer, Ralph ^a,c  

^a Merck Research Laboratories   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

^c IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; DICLOFENAC; MONOCLONAL ANTIBODY; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRITIUM;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; INSTRUMENTATION; INTERMETHOD COMPARISON; KINETICS; MASS SPECTROMETRY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOMETRY; SOLID PHASE EXTRACTION; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY;

ANTIBODIES, MONOCLONAL; ARYL HYDROCARBON HYDROXYLASES; AUTOMATION; DICLOFENAC; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; RADIOMETRY; REPRODUCIBILITY OF RESULTS; THEOPHYLLINE; TRITIUM; WATER;

EID: 14044278775     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.002915     Document Type: Article

References (29)

1. Bachmann KA and Ghosh R (2001) The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metab 2:299-314.
2. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
3. Bourne M, Meunier V, Berger Y, and Fahre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
4. Cohen LH, Remley MJ, Raunig D, and Vaz AD (2003) In vitro drug interactions of cytochrome P450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 31:1005-1015.
5. Crespi CL and Stresser DM (2000) Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Methods 44:325-331.
6. De Lean A and Rodbard D (1979) Kinetics of cooperative binding, in Receptors: Comprehensive Treatise (O'Brien RD ed) vol. 1, pp 143-192, Plenum, New York.
7. Di Marco A, Marcucci I, Verdirame M, Manuel Sanchez JP, Peláez F, Chaudhary A, and Laufer R (2005) Development and validation of a high-throughput radiometric CYP3A4 inhibition assay using tritiated testosterone. Drug Metab Dispos 33:349-358.
8. Draper AJ, Madan A, Smith K, and Parkinson A (1998) Development of a non-high pressure liquid chromatography assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes. Drug Metab Dispos 26:299-304.
9. Egnell AC, Eriksson C, Albertson N, Houston B, Boyer S, Bapiro TE, Hasler JA, and Masimirembwa CM (2003) Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. J Pharmacol Exp Ther 307:878-887.
10. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
11. Hummel MA, Gannett PM, Aguilar JS, and Tracy TS (2004) Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry 43:7207-7214.
12. Hutzler JM, Wienkers LC, Wahlstrom JL, Carlson TJ, and Tracy TS (2003) Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys 410:16-24.
13. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
14. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
15. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
16. Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, and Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749-759.
17. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
18. Moody GC, Griffin SJ, Mather AN, McGinnity DF, and Riley RJ (1999) Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 29:53-75.
19. Moser P, Sallmann A, and Wiesenberg I (1990) Synthesis and quantitative structure-activity relationships of diclofenac analogues. J Med Chem 33:2358-2368.
20. Northrop DB (1982) Deuterium and tritium kinetic isotope effects on initial rates. Methods Enzymol 87:607-625.
21. Oza VB, Smith C, Roman P, Koepf EK, Lashuel HA, Petrassi HM, Chiang KP, Powers ET, Sachettinni J, and Kelly JW (2002) Synthesis, structure and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem 45:321-332.
22. Riley RJ (2001) The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discovery Dev 4:45-54.
23. Rodbard D and Frazier GR (1975) Statistical analysis of radioligand assay data. Methods Enzymol 37:3-22.
24. Satoh Y, Stanton JL, Hutchison AJ, Libby AH, Kowalski TJ, Lee WH, White DH, and Kimble EF (1993) Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors. J Med Chem 36:3580-3594.
25. Schwarz UI (2003) Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Investig 33:23-30.
26. Shimada T, Yamazaki H, Mimura M, Wakamiya N, Ueng YF, Guengerich FP, and Inui Y (1996) Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 24:515-522.
27. Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, et al. (2001) Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 1:17-36.
28. Shou M, Lu T, Krausi KW, Sai Y, Yang T, Korzekwa KR, Gonzalez FJ, and Gelboin HV (2000) Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol 394:199-209.
29. Xie HG, Prasad HC, Kim RB, and Stein CM (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54:1257-1270.